Ontario

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Generic Name: BEVACIZUMAB

Brand Name: Abevmy

Strength: 25 mg/mL (400 mg/16 mL) and 25 mg/mL (100 mg/4mL) IV solution

Manufacturer: BGP Pharma ULC

Indications: Metastatic Colorectal Cancer (mCRC)

- ABEVMY in combination with fluoropyrimidine-based chemotherapy is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

- ABEVMY, in combination with carboplatin/paclitaxel chemotherapy regimen, is indicated for treatment of patients with unresectable advanced, metastatic or recurrent nonsquamous non-small cell lung cancer.

Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

- ABEVMY, in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens. These patients should not have received prior VEGF-targeted therapy including ABEVMY.

Malignant Glioma (WHO Grade IV) – Glioblastoma

- ABEVMY, in combination with lomustine, is indicated for the treatment of patients with glioblastoma after relapse or disease progression, following prior therapy.

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Status:
First Review: (Initial Submission)	15/11/2021	21/03/2022	EO decision rendered	Funding considered through Cancer Care Ontario's New Drug Funding Program

Review Status:

- Screening - Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete - Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review - Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs* (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed - A recommendation was made by the CED.
- Ontario Steering Committee for Cancer Drugs** (OSCCD) review completed - A recommendation was made by the OSCCD.
- Executive Officer (EO) decision rendered.

Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

The CED recommendation and the EO decision

* The Committee to Evaluate Drugs (CED) is the Ministry's independent expert advisory committee on drug-related issues. The committee is comprised of practicing physicians, pharmacists, health economists, and patient representatives. In conducting its review, the CED considers data contained in the drug manufacturer's submission, input provided by patient groups, findings from the national Common Drug Review and the pan-Canadian Oncology Drug Review, and other scientific information as necessary.

** The Ontario Steering Committee for Cancer Drugs (OSCCD) was created to enhance and support the administration of Ontario's cancer drug programs. The committee advises the Ministry of Health and Long-Term Care's Ontario Public Drug Programs and Cancer Care Ontario's Provincial Drug Reimbursement Programs.

Updated: April 29, 2022